Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Pfizer Inc. (PFE), the world’s biggest drugmaker, will analyze over the next eight months whether it will split itself into brand name and generics businesses, Chief Financial Officer Frank D’Amelio said. Pfizer hasn’t made a final decision on whether to break up the New York-based company and an official divide wouldn’t happen until at least 2016, Chief Executive Officer Ian Read said today. In the meantime, Pfizer is working to figure out whether its emerging markets operations would benefit from being organized more like its business in the U.S., Europe and Japan where the company has distinct brand and generics units, D’Amelio said today in a telephone interview. This “is a study year,” D’Amelio said. “What we don’t want to do is take the positive out of what the model’s already generating.”
Help employers find you! Check out all the jobs and post your resume.
Pfizer Inc. (PFE), the world’s biggest drugmaker, will analyze over the next eight months whether it will split itself into brand name and generics businesses, Chief Financial Officer Frank D’Amelio said. Pfizer hasn’t made a final decision on whether to break up the New York-based company and an official divide wouldn’t happen until at least 2016, Chief Executive Officer Ian Read said today. In the meantime, Pfizer is working to figure out whether its emerging markets operations would benefit from being organized more like its business in the U.S., Europe and Japan where the company has distinct brand and generics units, D’Amelio said today in a telephone interview. This “is a study year,” D’Amelio said. “What we don’t want to do is take the positive out of what the model’s already generating.”
Help employers find you! Check out all the jobs and post your resume.
